CoronaryAtlas logo
CoronaryAtlas
linoleic acid
Pathway / Off-pathway / systemic markers

linoleic acid

metabolite

Linoleic acid depletion in acute myocardial infarction reflects altered lipid metabolism, oxidative stress, and ischemia-reperfusion-mediated metabolic derangement.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationalePolyunsaturated fatty acid; dysregulated in AMI and ischemia-reperfusion injury.
Also acts inLipid entry/oxidation, Myocardial injury
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
68
C — confounder / Type-II
78
A — assay feasibility
42
E — evidence strength
31
T1DI (composite)
6
Specificity differential (R−C)-10.2
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(4)